<DOC>
	<DOCNO>NCT00526409</DOCNO>
	<brief_summary>The study objective improve global result obtain LAL-AR-93 study , reach event free survival 60-70 % . Identify patient bad prognosis , minimal residual disease , benefit allogenic bone marrow transplantation</brief_summary>
	<brief_title>LAL-AR-N-2005 : Study Treatment Children High Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>INDUCTION TREATMENT Systemic chemotherapy : PREDNISOLONE 60 mg/m2 /day , oral i.v . x 21 day ( 1 22 ) 30 mg/m2 /day , oral i.v . x 7 day ( 23 29 ) DAUNORUBICIN 30 mg/m2 , i.v . day 1,8,15 22 VINCRISTINE 1,5 mg/m2 , i.v . day 1,8,15 22 L-ASPARAGINASE 10.000U/m2 i.m i.v day 9,11,13,16,18,20,23,25 27 CYCLOPHOSPHAMIDE 500 mg/m2 i.v . day 1,2 29 Intrathecal chemotherapy : Days 1 22 accord age : Age &lt; 1 year 1-3 year &gt; 3 year Methotrexate ( MTX ) , mg 5 8 12 Ara-C , mg 16 20 30 Hydrocortisone , mg 10 10 20 Patients &lt; 10 % blast M.O ( day 14 ) , complete response week 5 6 , without MDR , start consolidation-intensification phase . Patients &gt; 10 % blast MO day +14 without CR induction treatment , start consolidation-intensification phase identifier donor transplantation . CONSOLIDATION/INTENSIFICATION ( C.I . ) Two sequential cycle , alternate bloc I bloc II BLOC I DEXAMETHASONE 10 mg/m2/d vo . day 1 5 5 mg/m2/d vo . day 6 7 VINCRISTINE 1.5 mg/m2/d , i.v . day 1 8 METHOTREXATE 5 g/m2 24 hour infusion + AF , day 1 ARA-C 1 g/m2/12 h , i.v. , day 5 6 MERCAPTOPURINE 100 mg/m2/d , oral , day 1 5 CYCLOPHOSPHAMIDE 500 mg/m2 i.v . el day +8 INTRATHECAL CHEMOTHERAPY day 1 . BLOC II DEXAMETHASONE 10 mg/m2/d , v o. day 1-5 5 mg/m2/d , v o. day 6 7 VINCRISTINE 1.5 mg/m2/d , day 1 8 METHOTREXATE 5 g/m2 24 h infusion + AF , day 1 ARA-C 1 g/m2 i.v/12 h , day 5 6 DAUNORUBICINE 30 mg/m2 i.v.day 1 L-ASPARAGINASE 20.000 u/m2/d , i.m . i.v . day 7 INTRATHECAL CHEMOTHERAPY day 1 Patients CR MRD negative , follow chemotherapy . Patients MDR &gt; 0.01 % second cycle consider previously MRD candidate allogenic transplantation second cycle . REINDUCTION/INTENSIFICATION TREATMENT ( R.I. ) PREDNISOLONE 60 mg/m2/d , oral x 14 day ( 1-14 ) 30 mg/m2/d , oral x 7 day ( 15-22 ) VINCRISTINE 1.5 mg/m2 , i.v . x 2 day 1 8 DAUNORUBICINE 30 mg/m2 i.v x 2 , day 1 8 CYCLOPHOSPHAMIDE 500 mg/m2 I.V . day 15 METHOTREXATE 3 g/m2 /24 h infusion + AF day 29 MERCAPTOPURINE 50 mg/m2/d , oral , day 29-35 43-50 ARA-C 1 g/m2/12 h. , i.v. , day 43 44 INTRATHECAL CHEMOTHERAPY , day 1 , 15 , 29 43 MAINTENANACE TREATMENT ( M1 ) Six cycle : MERCAPTOPURINE 50 mg/m2/d , oral x 21 day ( 1-21 ) METHOTREXATE 20 mg/m2/d , i.m . /week x 3 ( 1,7,14 ) PREDNISOLONE 60 mg/m2/d , oral x 7 day ( 22-28 ) VINCRISTINE 1.5 mg/m2 i.v.day 22 ASPARAGINASE 20.000 u/m2 i.m . day 22 INTRATHECAL CHEMOTHERAPY day 22 MAINTENANCE TREATMENT ( M2 ) Diary mercaptopurine weekly methotrexate previous dos , complete 24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>High risk child acute lymphoblastic leukemia Mature BALL ( FABL3 ) Mixed form ALL Patients coronary disorder , valvular hypertensive cardiopathy Patients chronic liver disorder Chronic pulmonary disorder Renal insufficiency Neurologic disfunction ECOG 3 4</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>